$1.10
8.91%
Nasdaq, Mon, Nov 25 2024
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Ocuphire Pharma Inc Stock price

$1.10
-0.07 5.98% 1M
-0.66 37.50% 6M
-1.91 63.46% YTD
-1.69 60.57% 1Y
-3.04 73.40% 3Y
-6.54 85.60% 5Y
-330.05 99.67% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.09 8.91%
ISIN
US67577R1023
Symbol
OCUP
Sector
Industry

Key metrics

Market capitalization $34.73m
Enterprise Value $-1.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.14
EV/Sales (TTM) EV/Sales -0.23
P/S ratio (TTM) P/S ratio 4.14
P/B ratio (TTM) P/B ratio 0.84
Revenue growth (TTM) Revenue growth -85.35%
Revenue (TTM) Revenue $8.38m
EBIT (operating result TTM) EBIT $-29.47m
Free Cash Flow (TTM) Free Cash Flow $-13.59m
Cash position $36.64m
EPS (TTM) EPS $-1.09
P/E forward negative
P/S forward 2.30
EV/Sales forward negative
Short interest 3.74%
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocuphire Pharma Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.38 8.38
85% 85%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
32% 32%
169%
- Research and Development Expense 24 24
36% 36%
282%
-29 -29
201% 201%
-352%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
201% 201%
-352%
Net Profit -27 -27
195% 195%
-324%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
PRNewsWire
about one month ago
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmac...
Neutral
Business Wire
about one month ago
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Ocuphire will issue 5.2 million shares of its common sto...
Neutral
GlobeNewsWire
about one month ago
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Employees 14
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today